Streetbeat News

DRUG

Bright Minds Biosciences Inc.

Industry

Biotechnology

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Open

35.62

Mkt cap

252M

Volume

30K

High

36.77

P/E Ratio

-255.57

52-wk high

79.02

Low

35.62

Div yield

N/A

52-wk low

0.93

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) is set to launch REZENOPY®, a naloxone nasal spray for opioid overdose treatment, in collaboration with Kindeva Drug Delivery. This follows FDA approval in April 2024.

Portfolio Pulse from

March 06, 2025 | 1:00 pm

Bright Minds Biosciences is advancing its BMB-101 drug targeting drug-resistant epilepsy, aiming for a multibillion-dollar market. The company is conducting a phase 2 trial for Absence Epilepsy and DEE, with data expected by 2026. A $35 million private placement extends its cash runway beyond 2026, supporting its pipeline.

Portfolio Pulse from

January 26, 2025 | 11:45 am

Bright Minds Biosciences has appointed Dr. Stephen Collins as Chief Medical Officer, bringing his extensive expertise in drug development and clinical work in epilepsy. This move is expected to strengthen the company's focus on developing treatments for CNS disorders.

Portfolio Pulse from

January 07, 2025 | 12:00 pm

Cumberland Pharmaceuticals has received FDA Orphan Drug and Rare Pediatric Disease designations for Ifetroban, a treatment for cardiomyopathy associated with Duchenne muscular dystrophy.

Portfolio Pulse from

November 06, 2024 | 10:30 pm

Bright Minds Biosciences (NASDAQ:DRUG) shares are trading higher following a new collaboration with Firefly Neuroscience for EEG data analysis in their BREAKTHROUGH study. The stock previously soared 1,445% in a day, despite no specific news, and announced a private placement for R&D funding.

Portfolio Pulse from Adam Eckert

October 21, 2024 | 2:33 pm

Bright Minds Biosciences experienced a trading halt due to a circuit breaker triggered by a sharp decline. However, the stock rebounded and is now up by 13.7%.